• Follow Us On : 

Jacobson Pharma Announces FY2020 Interim Results

Redaksi | Selasa,26 November 2019 - 12:57:20 WIB
Dibaca: 1158 kali 
Jacobson Pharma Announces FY2020 Interim Results
  • Profit Attributable to Shareholders Lifted by 30.5%
  • Portfolio and Market Expansion to Harness Growth Potentials

CHINA - Media OutReach - 26 November 2019 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2019 (the "reporting period").

During the reporting period, the Group maintained a steady growth with its revenue and gross profit increased by 6.8% and 12.5% to HK$871.7 million (1H2018: HK$816.3 million) and HK$358.5 million (1H2018: HK$318.7 million) respectively. Profit from operations rose by 18.3% to HK$187.7 million (1H2018: HK$158.6 million). Profit attributable to the shareholders of the Company leapt by 30.5% to HK$127.2 million (1H2018: HK$97.5 million). Basic and diluted earnings per share were HK6.32 cents (1H2018: HK5.28 cents).

The Group maintains a healthy financial position with cash and cash equivalents of HK$718.2 million at the end of the reporting period. The Board has declared payment of an interim dividend for the six months ended 30 September 2019 of HK2.0 cents per share (1H2018: HK1.5 cents).

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, comments, "Focusing on our strategic growth plan, we have achieved promising progress on the business development front in terms of enhancing our product offerings and establishing a competitive regional commercial platform. Riding on our established competences and growth momentum, we have further strengthened our position as an eminent market player and have been successfully forging strategic collaborations with multinational partners covering in-licensing, technology transfer and representation of both generic drugs and branded healthcare products in the Greater China and Asia Pacific region."

Sustained Growth for Generic Drugs
The Group's generic drugs business delivered a stable growth of 5.3% for a revenue at approximately HK$626.9 million during the reporting period which was mainly driven by the expanded product offerings of the Group along with the rising healthcare demands resulted from aging population and prevalence of chronic diseases. Nonetheless, growth in the private sector has been undermined to certain extent by weakened retail performance across Hong Kong in the past few months.

Emerging demand for generic drugs from private sector will be catalyzed by the evolving government programs aiming to integrate certain primary healthcare services with private practices in the attempt to alleviate strains in public healthcare system, such as the General Outpatient Clinic Public-Private Partnership Program which has now been participated by around 30,000 public hospital patients suffering from hypertension, diabetes mellitus or hyperlipidemia since its launched in 2014. The Glaucoma Public-Private Partnership Program was newly introduced in 2019 aiming to provide choice to patients for receiving private specialist services in the community.

Resilience of Proprietary Medicine Brands
Referring to the sales performance of the Group's proprietary medicines business, a modest growth was maintained during the reporting period despite the continued turmoil to the local retail industry. With the incorporation of a newly acquired proprietary Chinese medicine business, the total revenue from this segment of the Group amounted to HK$130.3 million, up by 17.7%.

In particular, Po Chai Pills, the Group's leading Chinese gastrointestinal medicine brand, delivered a decent growth of 11.0% in its Hong Kong and Macau business in terms of sales revenue during the reporting period. Ho Chai Kung, a widely recognized heritage brand in the analgesics category of the Group, also delivered a notable growth of 27.3% in Hong Kong and Macau. Shiling Oil, a medicated oil brand of the Group, has been delivering a strong growth momentum in overseas markets presenting a 28.8% increase in sales revenue during the reporting period.

Portfolio Enhancement for High Value-added Offerings
To supplement the R&D pipeline and broaden the portfolio of specialty drugs for tapping new potentials of the market, the Group has been actively forging collaborations with strategic partners in exploiting market opportunities in the Asia Pacific region. During the Reporting Period, the Group has signed exclusive in-license agreements for a total of 19 specialized drugs with reputable manufacturers in Greece, Spain, South Korea and Taiwan. Among them, 12 items are eligible for tender bidding in the coming years.

The Group has also had a head start for the launch of two medical nutrition products in Hong Kong, namely Aterinorm from Difass in Italy and Gynositol from Indigo in France, targeting the functional food and Food for Special Medical Purpose (FSMP) markets. While in the consumer nutrition arena, the Group has entered into an in-license agreement with Smartfish from Norway in a strategic collaboration to launch its clinically-tested health and sports nutrition drinks in Asia.

In addition, the recently-formed joint venture alliance with Weisen-U「胃仙-U」and Flucur Nebuliser「呼佳噴霧劑」, as well as the exclusive distributorship for the highly recognized medicated nail and foot care brand Excilor「恢甲清」, have also enhanced the Group's portfolio and further strengthened its market position in capitalizing on the rising consumer demand for quality branded healthcare products in the burgeoning China and Asia markets.

Mr. Sum remarks "Looking ahead, we will continue to build momentum with the strategically-aligned growth plans driving us forward. We aspire to be an eminent player in essential medicines and consumer healthcare solutions in Asia. We remain well-positioned with a balanced portfolio, a strong R&D pipeline and a sound commercial platform which will facilitate the delivery of sustainable growth for our businesses over the long term."

Akses Wahanariau.com Via Mobile m.Wahanariau.com
Untuk Berbagi Berita / Informasi / Peristiwa
Silahkan SMS ke nomor HP : 085271472010
atau email ke alamat : [email protected]
Harap camtumkan detail data diri Anda
Pengutipan Berita dan Foto, Cantumkan Wahanariau.com Sebagai Sumber Tanpa Penyingkatan
Jumat,03 Mei 2019

Jacobson Pharma Issues Positive Profit Alert

Expects to Record Over 20% Increase in Profit Attributable to Shareholders CHINA - 2 May 2019

Rabu,23 September 2020

Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business

CHINA - Media OutReach - 23 September 2020 - Jacobson Pharma Corporation Limited ("Jacobson Pha

Jumat,15 Januari 2021

Jacobson Pharmas Proposed Spin-off and Separate Listing of JBM Limited on The Main Board of The Stock Exchange of Hong Kong Limited

Declaration of Conditional Special Interim Dividend HONG KONG SAR - 15 January 2021 - Jacobson Phar

Senin,25 Januari 2021

JBM Limited to Be Spun Off from Jacobson Pharma Corporation Limited

Announces Details of Proposed Listing on Main Board of SEHK Highlights The fourth largest brand o

Jumat,26 November 2021

Jacobson Pharma Announces FY2022 Interim Results

Robust Growth of 11.6% in Generics Business Amidst the Pandemic; Confident about Sustaining Str

Selasa,29 Juni 2021

Jacobson Pharma Announces FY2021 Annual Results

Declares Final Dividend of HK1.5 Cents Per Share; Resilient Performance Albeit Market Challenges HO

Kamis,02 Februari 2023

Carousell Group Integrates Laku6 Team, AI-first Diagnostics Technology to Drive Mobile Recommerce Expansion Across Greater Southeast Asia

SINGAPORE - 2 February 2023 - Harnessing the scale of two million listings listed in the electronics

Kamis,02 Februari 2023

Asian Stationery & Office Products Online Exhibition 2023 Grand Opening

TAIPEI - 2 February 2023 - Asian Stationery & Office Products Online Exhibition (ASOP 2023) is a

Kamis,02 Februari 2023

ThreatLocker® Unveils the Future of Zero Trust with New Products

Global Cybersecurity leader unifies critical components of their stack with new Ops and other featur